Agomelatine as a novel treatment option in panic disorder, results from an 8-week open-label trial.

Huijbregts, Klaas M; Batelaan, Neeltje M; Schonenberg, Judy; Veen, Gerthe; van Balkom, Anton J

Huijbregts, Klaas M; Batelaan, Neeltje M; Schonenberg, Judy; Veen, Gerthe; van Balkom, Anton J.

Afiliação

Huijbregts KM; Department of Psychiatry VU University Medical Centre and Department of Anxiety and Depression GGZ inGeest Amsterdam, The Netherlands khuijbregts@gmail.com Department of Psychiatry VU University Medical Centre Department of Anxiety and Depression GGZ inGeest and EMGO Institute for Health and Care Research (EMGO+) Amsterdam, The Netherlands Department of Psychiatry VU University Medical Centre, and GGZ inGeest Amsterdam, The Netherlands Department of Psychiatry VU University Medical Centre and De

J Clin Psychopharmacol ; 35(3): 336-8, 2015 Jun.

Article em En | MEDLINE | ID: mdl-25856784

Assuntos

Acetamidas/uso terapêutico; Ansiolíticos/uso terapêutico; Transtorno de Pânico/tratamento farmacológico; Feminino; Humanos; Masculino; Pessoa de Meia-Idade

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Ansiolíticos / Transtorno de Pânico / Acetamidas Limite: Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Psychopharmacol Ano de publicação: 2015 Tipo de documento: Article

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google